Finance

Lists
RCEL:NASDAQ
AVITA Medical Inc
13,21 $
+1,30%
(+0,17) 1D
19 қаз., 15:30:44 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCEL...
Open
13,01 $
High
13,44 $
Low
12,70 $
Mkt. cap
407,15 млн
Avg. vol.
323,00 м.
Volume
190,00 м.
52-wk high
13,73 $
52-wk low
3,22 $
EPS
-1,44 $
Beta
1,99
Shares outstanding
30,93 млн
No. of employees
226
Open
13,01 $
High
13,44 $
Low
12,70 $
Mkt. cap
407,15 млн
Avg. vol.
323,00 м.
Volume
190,00 м.
52-wk high
13,73 $
52-wk low
3,22 $
EPS
-1,44 $
Beta
1,99
Shares outstanding
30,93 млн
No. of employees
226
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
2 сағат бұрын
What Comes Next For AVITA Medical After A 276% Gain
Profile
Avita Medical is a clinical and commercial company developing and marketing a range of regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts. Wikipedia
About AVITA Medical Inc
CEOJames Corbett
Employees226
Founded1999
HeadquartersValencia, Калифорния, Америка Құрама Штаттары
Sector-
Analyst ratings
Based on 3 analysts giving stock ratings to RCEL in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for RCEL in the last 3 months.
Highest
Current 13,21 $
15,00 $ (+13,55%)
Average
13,67 $ (+3,48%)
Lowest
12,00 $ (-9,16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ryan Zimmerman
BTIG
Buy
Maintained
15,00 $
+13,6%
10/12/2026
Josh Jennings
TD Cowen
Buy
Maintained
14,00 $
+6%
09/17/2026
Frank Takkinen
Lake Street
Buy
Reiterated
12,00 $
-9,2%
08/28/2026
Chad Messer
Lake Street
Buy
Reiterated
6,00 $
-54,6%
07/16/2026
Carl Byrnes
Northland Securities
Buy
Maintained
10,00 $
-24,3%
03/26/2026
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
17,06 млн
17,62 млн
19,25 млн
21,70 млн
Cost of goods sold
3,19 млн
3,30 млн
3,52 млн
3,94 млн
Cost of revenue
3,19 млн
3,30 млн
3,52 млн
3,94 млн
Research and development expenses
3,75 млн
5,69 млн
5,63 млн
5,08 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19,28 млн
19,03 млн
18,90 млн
19,54 млн
Operating expense
23,03 млн
24,72 млн
24,53 млн
24,62 млн
Total operating expenses
26,22 млн
28,02 млн
28,05 млн
28,56 млн
Operating income
-9,15 млн
-10,41 млн
-8,80 млн
-6,86 млн
Other non operating income
49,00 мың
737,00 м.
-95,00 мың
-12,00 мың
EBT including unusual items
-13,17 млн
-11,64 млн
-10,62 млн
-7,63 млн
EBT excluding unusual items
-12,27 млн
-11,04 млн
-10,32 млн
-7,83 млн
Income tax expense
15,00 мың
-17,00 мың
-11,00 мың
33,00 мың
Effective tax rate
-0,11%
0,15%
0,10%
-0,43%
Other operating expenses
-
-
-
-
Net income
-13,19 млн
-11,62 млн
-10,61 млн
-7,66 млн
Net profit margin
-77,29%
-65,97%
-55,12%
-35,31%
Earnings per share
-
-
-
-
Interest and investment income
300,00 м.
200,00 м.
-
500,00 м.
Interest expense
-3,47 млн
-1,55 млн
-1,42 млн
-1,46 млн
Net interest expenses
-3,17 млн
-1,35 млн
-1,42 млн
-963,00 м.
Depreciation and amortization charges
-
-
-
-
EBITDA
-8,58 млн
-9,76 млн
-8,18 млн
-6,25 млн
Gain or loss from assets sale
252,00 м.
5,00 мың
55,00 мың
188,00 м.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары